

## Pharma in brief - Canada

### Health Canada releases white paper – Public Release of Clinical Information in Drug Submissions and Medical Device Applications

---

#### Summary

Health Canada released the white paper – Public Release of Clinical Information in Drug Submissions and Medical Device Applications. The white paper sets out Health Canada’s decision to make certain clinical information from drug submissions and medical device applications available to the public following regulatory review. Stakeholders may provide comments on the white paper using [Health Canada’s online form](#). The consultation period is open until **May 26, 2017**.

#### Overview

Currently, clinical information submitted by drug and medical device manufacturers used to assess the safety and efficacy of a drug or device is maintained as confidential business information. The white paper states that this information is far more comprehensive than that found in other sources such as scientific journals and clinical trial registries.

Health Canada is proposing that certain clinical information contained in drug submissions and medical device applications will be made publicly available for “non-commercial” purposes following regulatory review. The white paper defines “non-commercial” as information that “will not be used to support a marketing authorization application anywhere in the world or sold, or traded to another person.”

#### Policy rationale

The policy rationale for the public release of information is to support the Government of Canada’s commitment to transparency and accountability and to increase public confidence in the regulatory decision-making process.

The white paper states that public access to clinical information will enable independent analyses of the clinical data contained in submissions, which will (i) benefit clinical trial participants by preventing duplication of research that unnecessarily exposes participants to harm and (ii) benefit patients and healthcare providers by enabling better informed health decisions, and promoting appropriate use of the drug or device.

The public release of confidential information also brings Canada in line with other jurisdictions such as the United States and Europe, which have developed policies to share clinical trial information.

#### Health Canada’s proposed approach

Health Canada intends to develop draft regulations that will amend the *Food and Drug Regulations* and the *Medical Devices Regulations*.

The amendments to the *Food and Drug Regulations* would provide that following a final regulatory decision, clinical summaries, reports and supporting data of completed clinical trials for primary, secondary outcomes or exploratory endpoints that are not part of an ongoing clinical development program will cease to be confidential business information.

Similar amendments are proposed to the *Medical Devices Regulations* for summaries and detailed information of all completed clinical studies or investigational testing in humans for primary, secondary outcomes or exploratory endpoints that are not part of an ongoing clinical development program.

Stakeholders will be consulted on implementation of the proposed approach, including processes for review and redaction, mechanisms for public release of clinical information and safeguards against commercial use.

## Links:

[Government of Canada Notice.](#)

[White Paper – Public Release of Clinical Information in Drug Submissions and Medical Device Applications](#)

---

For more information, please contact your IP/Life sciences or healthcare practice professional at Norton Rose Fulbright Canada LLP.

For a complete list of our IP team, [click here](#). For a complete list of our Life sciences and healthcare team, [click here](#).

Norton Rose Fulbright Canada LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright South Africa Inc and Norton Rose Fulbright US LLP are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients.

References to "Norton Rose Fulbright", "the law firm", and "legal practice" are to one or more of the Norton Rose Fulbright members or to one of their respective affiliates (together "Norton Rose Fulbright entity/entities"). No individual who is a member, partner, shareholder, director, employee or consultant of, in or to any Norton Rose Fulbright entity (whether or not such individual is described as a "partner") accepts or assumes responsibility, or has any liability, to any person in respect of this communication. Any reference to a partner or director is to a member, employee or consultant with equivalent standing and qualifications of the relevant Norton Rose Fulbright entity.

The purpose of this communication is to provide general information of a legal nature. It does not contain a full analysis of the law nor does it constitute an opinion of any Norton Rose Fulbright entity on the points of law discussed. You must take specific legal advice on any particular matter which concerns you. If you require any advice or further information, please speak to your usual contact at Norton Rose Fulbright.